Disclosed is a liquid formulation of etanercept, comprising etanercept; and methionine or pharmaceutically acceptable salts thereof as a stabiliser, wherein the formulation has increased storage stability of etanercept compared to the formulation comprising arginine as a stabiliser, by reducing etanercept by-products that are produced due to denaturation during storage.